Mylan Exudes Confidence About Plan For Biogenerics
This article was originally published in The Pink Sheet Daily
At a Feb. 21 investor day, Mylan discussed its long-term goals for launching several biosimilars, as well some hard-to-reproduce generic offerings.
You may also be interested in...
Mylan: Brand/Generic Distinction Disintegration Is Necessary
Consolidation in the generic industry is good and necessary, Mylan CEO Heather Bresch said during a recent investor presentation. Mylan is well-positioned in the changing market, she said, thanks to business development such as its biosimilars agreements with Biocon and its Japan collaboration with Pfizer.
Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva
The company is borrowing a page, and a law firm, from GlaxoSmithKline’s 2009 citizen petition asking FDA to impose conditions on generic Advair.
Mylan Breathes Life Into Its Specialty Pharma Unit
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.